

Draft Guidance on Sotalol Hydrochloride

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

Active ingredient: Sotalol Hydrochloride

Form/Route: Tablet/Oral

Recommended studies: 2 Options: BCS or *In-Vivo* Studies

I. BCS Waiver option:

It may be possible to request a waiver of *in-vivo* testing for all the strengths of this product provided that the appropriate documentation regarding high solubility, high permeability and rapid dissolution as detailed in the Guidance for Industry: *Waiver of In Vivo Bioavailability and Bioequivalence for Immediate – Release Solid Oral Dosage Forms Based on the Biopharmaceutics Classification System* is submitted in the application. You may use information contained in the approved labeling of the reference product. Peer reviewed articles may not contain the necessary details of the testing for the Agency to make a judgment regarding the quality of the studies. A decision regarding the acceptability of the waiver request can only be made upon review of the data submitted in the application.

II. *In-Vivo* option:

1. Type of study: Fasting
Design: Single-dose, two-way crossover *in-vivo*
Strength: 160 mg
Subjects: Healthy males and nonpregnant females, general population
Additional Comments:

2. Type of study: Fed
Design: Single-dose, two-way crossover *in-vivo*
Strength: 160 mg
Additional Comments: Please refer to the Amantadine Hydrochloride Tablet Draft Guidance for additional information regarding fed studies.

Analyte to measure: Sotalol in plasma

Bioequivalence based on (90% CI): Sotalol

Waiver request of in-vivo testing: 80 mg and 120 mg based on (i) acceptable bioequivalence studies on the 160 mg strength, (ii) proportional similarity of the 80 mg, 120 mg, and 160 mg strengths, and (iii) acceptable in vitro dissolution testing of all strengths. Please refer to the Mirtazapine Tablet Draft Guidance for additional information regarding waivers of in-vivo testing.

Dissolution test method and sampling times:

Please note that a **Dissolution Methods Database** is available to the public at the OGD website at <http://www.accessdata.fda.gov/scripts/cder/dissolution/>. Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.